表紙
市場調查報告書
商品編碼
997343

市場焦點:乾燥綜合徵

Market Spotlight: Sjogren's Syndrome

出版日期: | 出版商: Datamonitor Healthcare | 英文 32 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

據估計,2019年世界範圍內原發性乾燥綜合徵的患病率約為226萬,預計到2028年將增至252萬。

原發性乾燥綜合徵在女性中很常見。在全球範圍內,據估計,在2019年,年齡在15歲以上的病例中90.41%是女性。

Evoxac是一種M1受體特異性毒蕈鹼激動劑,LO2A含有等滲甘油和0.015%透明質酸鈉,是批准用於乾燥綜合徵的唯一藥物。

大多數在臨床上積極發展的乾燥綜合徵的行業贊助藥物處於II期,只有一種處於III期。

乾燥綜合徵發展中的治療方法集中在各種各樣的靶標上。乾燥綜合徵藥物通過口服,靜脈內或皮下途徑給藥。

該市場聚焦報告涵蓋了主要的非處方藥和在售藥物,臨床試驗,近期事件和分析師意見,許可和資產收購交易,成功的可能性以及10年的疾病流行率。乾燥綜合徵市場,包括預測。

目錄

內容

概述

要點

疾病背景

治療

  • 乾眼
  • 口渴
  • 其他腺體症狀
  • 腺外症狀

流行病學

非處方藥

管道醫學

最近發生的事件和分析師的觀點

  • 斯格倫綜合徵的伊斯卡利單抗(2020年1月23日)
  • 多種用於治療乾燥綜合徵的藥物(2019年10月24日)

成功的可能性

許可和資產收購交易

  • Horizo□□n以30億美元收購Viela來構建管道

臨床試驗情況

  • 按狀態贊助
  • 分階段贊助

參考

  • 處方信息

附錄

數字列表

表列表

目錄
Product Code: DMKC0182069

Overview:

This Market Spotlight report covers the Sjogren's Syndrome market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, licensing and asset acquisition deals, probability of success, and a 10-year disease prevalence forecast.

Datamonitor Healthcare estimates that in 2019, there were approximately 2.26 million prevalent cases of primary Sjogren's syndrome worldwide, and forecasts that number to increase to 2.52 million prevalent cases by 2028.

Primary Sjogren's syndrome has a female predominance. Globally, Datamonitor Healthcare estimates that in 2019, 90.41% of cases aged 15 years and over were female.

Evoxac, a muscarinic agonist specific to M1 receptors, and LO2A, which contains isotonic glycerol and 0.015% sodium hyaluronate, are the only approved drugs for Sjogren's syndrome.

The majority of industry-sponsored drugs in active clinical development for Sjogren's syndrome are in Phase II, with only one drug in Phase III.

Therapies in development for Sjogren's syndrome focus on a wide variety of targets. The pipeline drugs for Sjogren's syndrome are administered via the oral, intravenous, and subcutaneous routes.

The overall likelihood of approval of a Phase I arthritis asset is 8.4%, and the average probability a drug advances from Phase III is 80%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 9.2 years in the overall autoimmune/immunology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for Sjogren's syndrome have been in the early and mid-phases of development, with 78% of trials in Phase I-II, and only 22% in Phase III-IV.

The US has the highest number of Sjogren's syndrome clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the Sjogren's syndrome space is dominated by completed trials. Novartis has the highest number of completed clinical trials for Sjogren's syndrome, with eight trials.

Bristol Myers Squibb and Novartis lead the industry sponsors with the highest overall number of clinical trials for Sjogren's syndrome.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Dry eyes
  • Dry mouth
  • Other glandular manifestations
  • Extraglandular manifestations

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Iscalimab for Sjogren's Syndrome (January 23, 2020)
  • Multiple Drugs for Sjogren's Syndrome (October 24, 2019)

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • With $3bn Viela Acquisition, Horizon Builds A Pipeline

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of primary Sjogren's syndrome, 2019-28
  • Figure 2: Overview of pipeline drugs for Sjogren's syndrome in the US
  • Figure 3: Pipeline drugs for Sjogren's syndrome, by company
  • Figure 4: Pipeline drugs for Sjogren's syndrome, by drug type
  • Figure 5: Pipeline drugs for Sjogren's syndrome, by classification
  • Figure 6: Iscalimab for Sjogren's Syndrome (January 23, 2020): Phase II - Primary Sjogren
  • Figure 7: Probability of success in the arthritis pipeline
  • Figure 8: Clinical trials in Sjogren's syndrome
  • Figure 9: Top 10 drugs for clinical trials in Sjogren's syndrome
  • Figure 10: Top 10 companies for clinical trials in Sjogren's syndrome
  • Figure 11: Trial locations in Sjogren's syndrome
  • Figure 12: Sjogren's syndrome trials status
  • Figure 13: Sjogren's syndrome trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of primary Sjogren's syndrome, 2019-28
  • Table 2: Prevalent cases of primary Sjogren's syndrome, by gender, 2019
  • Table 3: Marketed drugs for Sjogren's syndrome
  • Table 4: Pipeline drugs for Sjogren's syndrome in the US
  • Table 5: Iscalimab for Sjogren's Syndrome (January 23, 2020)
  • Table 6: Multiple Drugs for Sjogren's Syndrome (October 24, 2019)